Connor, Clark & Lunn Investment Management (CC&L)’s BioMarin Pharmaceuticals BMRN Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q2 | $22.2M | Sell |
|
|||||
|
2025
Q1 | $36.9M | Buy |
|
|||||
|
2024
Q4 | $23.4M | Buy |
|
|||||
|
2024
Q3 | $8.17M | Buy |
|
|||||
|
2023
Q4 | – | Sell |
|
|||||
|
2023
Q3 | $468K | Sell |
|
|||||
|
2023
Q2 | $1.24M | Sell |
|
|||||
|
2023
Q1 | $22.4M | Sell |
|
|||||
|
2022
Q4 | $32.9M | Buy |
|
|||||
|
2022
Q3 | $17.1M | Sell |
|
|||||
|
2022
Q2 | $20.5M | Buy |
|
|||||
|
2022
Q1 | $12M | Buy |
|
|||||
|
2021
Q4 | $1.18M | Sell |
|
|||||
|
2021
Q3 | $5.51M | Buy |
|
|||||
|
2021
Q2 | $1.73M | Buy |
|
|||||
|
2021
Q1 | $589K | Sell |
|
|||||
|
2020
Q4 | $2.23M | Buy |
|
|||||
|
2020
Q3 | $693K | Buy |
|
|||||
|
2020
Q2 | $952K | Buy |
|
|||||
|
2020
Q1 | – | Sell |
|
|||||
|
2019
Q4 | $744K | Buy |
|
|||||
|
2019
Q3 | $551K | Buy |
|
|||||
|
2019
Q2 | $454K | Buy |
|
|||||
|
2018
Q2 | – | Sell |
|
|||||
|
2018
Q1 | $511K | Sell |
|
|||||
|
2017
Q4 | $624K | Sell |
|
|||||
|
2017
Q3 | $1.79M | Buy |
|
|||||
|
2017
Q2 | $245K | Buy |
|
|||||
|
2016
Q3 | – | Sell |
|
|||||
|
2016
Q2 | $513K | Sell |
|
|||||
|
2016
Q1 | $1.53M | Buy |
|
|||||
|
2015
Q4 | – | Sell |
|
|||||
|
2015
Q3 | $516K | Buy |
|
|||||
|
2014
Q1 | – | Sell |
|
|||||
|
2013
Q4 | $436K | Buy |
|